different drug, different mechanism of action, different protein target (membrane-bound rather than soluble), and different indication
really quite irrelevant to efti, only downside is imm will miss out on some future milestone payments but the company is funded through 2022 so not a huge deal
im sure the market will overreact though
Ann: Ulcerative Colitis Phase II Study of GSK2831781 Discontinued, page-7
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
31.5¢ |
Change
-0.005(1.56%) |
Mkt cap ! $458.1M | |||
| Open | High | Low | Value | Volume |
| 32.0¢ | 32.8¢ | 31.0¢ | $1.817M | 5.763M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 71665 | 31.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.0¢ | 36363 | 2 |
View Market Depth
| Last trade - 16.10pm 15/10/2024 (20 minute delay) ? |
| IMM (ASX) Chart |